Drugs / LBVE014
last change Nov 2016 re-read 2 minutes ago

LBVE014

Vaccine

Developed for
pneumococcal infection
Investigated by
LG Life Sciences

Trials 1 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02892812 Sep → Nov 2016 pneumococcal infection LG Life Sciences Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as LBVE014 LBVE014 (Pneumococcal 14-valent Conjugate Vaccine [Diphtheria CRM197 Protein])” NCT02892812
Modality Vaccine “Pneumococcal 14-valent Conjugate VaccineNCT02892812
Route Intramuscular Intramuscular Single Injection” NCT02892812